Back to results

Syracuse University

The Path to an Orally Administered Protein Therapeutic for the Treatment of Diabetes Mellitus

Abstract

dc:description.abstract

<p>Protein therapeutics like insulin and glucagon-like peptide-1 analogues are currently used as injectable medications for the treatment of diabetes mellitus. An orally administered protein therapeutic is predicted to increase patient adherence to medication and bring a patient closer to metabolic norms through direct effects on hepatic glucose production. The major problem facing oral delivery of protein therapeutics is gastrointestinal tract hydrolysis/proteolysis and the inability to passage the enterocyte. Herein we report the potential use of vitamin B<sub>12</sub> for the oral delivery of protein therapeutics.</p> <p>We first investigated the ability of insulin to accommodate the attachment of B<sub>12</sub> at the B1 vs. B29 amino acid position. The insulinotropic profile of both conjugates was evaluated in streptozotocin induced diabetic rats. Oral administration of the conjugates produced significant drops in blood glucose levels, compared to an orally administered insulin control, but no significant difference was observed between conjugates. We also report, for the first time, a dose dependent response of a B<sub>12</sub>-insulin conjugate. We then explored the implications of B<sub>12</sub> conjugation on the biological activity of the potent peptide glucagon-like peptide-1 (7-36) amide, with a K34R amino acid substitution. Various in vitro bioassays utilizing human embryonic kidney cells and human pancreatic islets were conducted and indicated B<sub>12</sub> has a minimally negative effect on GLP-1 biological activity. Finally we modified the structure of B<sub>12</sub> for future conjugation work. The modification of the 5'hydroxyl group of the ribose unit of B<sub>12</sub> to a carboxylic acid is predicted to benefit the field of B<sub>12</sub> conjugation significantly with the ability to produce higher yielding and more stable B<sub>12</sub> conjugates.</p>

Degree

thesis:*
Name thesis:degree_name
Doctor of Philosophy (PhD)
Level thesis:degree_level
Dissertation
Discipline thesis:degree_discipline
Chemistry
Year
2012

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • James, Susan Clardy
Contributors dc:contributor
  • Robert P. Doyle

Subjects

dc:subject × 5

Identifiers

dc:identifier.*
Repository record dc:identifier
https://surface.syr.edu/che_etd/196
OAI identifier oai:identifier
oai:surface.syr.edu:che_etd-1196

Chain of custody

source
Harvested from
Syracuse University
Base URL
surface.syr.edu/do/oai/
Last updated
2026-07-24
Source record
OAI-PMH GetRecord
citation

James, Susan Clardy. The Path to an Orally Administered Protein Therapeutic for the Treatment of Diabetes Mellitus. Dissertation thesis, 2012. https://surface.syr.edu/che_etd/196